Climb Bio
CLYM12.0800.25% ( -0.030 )
Climb Bio (CLYM)
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated disease...
- Open
- 12.390
- High
- 12.790
- Low
- 12.040
- Prev. Close
- 12.110
- Volume
- 1.80M
- Turnover
- 22.48M
- Avg Price
- 12.493
- Bid/Ask Ratio
- --
- Amplitude
- 6.19%
- 52wk High
- 14.415
- Volume Ratio
- 1.65
- Turnover Ratio
- 6.45%
Climb Bio Analyst Rating
View MoreForecast & Rating
Jul 30, 2026Price forecast
$20.9373.25%
Forecast & RatingStrong buy
14analysts
- Strong buy92.86%
- Buy7.14%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 28 at 04:13 AM
Beyond the Algorithm: What 10 Fringe Stocks Tell Us About the Market
- Market Beat · Jul 27 at 09:20 AM
Climb Bio (NASDAQ:CLYM) Trading 10.9% Higher After Analyst Upgrade
- Market Beat · Jul 27 at 08:18 AM
Wedbush Forecasts Strong Price Appreciation for Climb Bio (NASDAQ:CLYM) Stock
- Tip Ranks · Jul 21 at 02:01 PM
Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target
- Market Beat · Jul 17 at 12:00 PM
Climb Bio (NASDAQ:CLYM) Shares Up 6.7% - Should You Buy?
- rttnews · Jul 6 at 04:55 AM
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?
